Revvity has announced a collaboration with pharmaceutical giant Sanofi to create a test for early-stage Type 1 diabetes screening. This initiative aims to enhance patient outcomes by intervening early to halt the disease’s progression. Revvity, based in Waltham, Massachusetts, is developing a four-plex in vitro diagnostic test to detect four autoantibodies indicative of the early stages of Type 1 diabetes. Utilizing both dried blood spot and venous blood specimens, the test builds on Revvity’s existing three-plex assay, currently limited to research use. The partnership will focus on clinical validation and regulatory clearances for the new assay on Revvity’s GSP instrument, targeting approvals in the U.S., Europe, and beyond. Sanofi’s Shirley Gil Parrado emphasized that expanding autoantibody testing to platforms like Revvity GSP could set a new standard of care by enabling earlier diagnosis of Type 1 diabetes. Additionally, Revvity and Sanofi aim to broaden access to Revvity’s research-use-only product, currently available as a lab-developed test in Pittsburgh, by validating the assay across Revvity’s global lab network. Meanwhile, Kihealth has secured $5 million in seed funding to support the launch of its test that measures biomarkers of beta cell death, an early sign of insulin resistance and diabetes, through a simple blood draw. This test assesses pancreatic beta cell viability, identifying high-risk individuals before glucose or A1c irregularities manifest.
Are Revvity and Sanofi advancing early Type 1 diabetes detection?
